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Abstract The Juvenile Diabetes Research Foundation
(JDRF) Network for Pancreatic Organ Donors with Diabetes
(JDRF nPOD) was established to obtain human pancreata and
other tissues from organ donors with type 1 diabetes (T1D) in
support of research focused on disease pathogenesis. Since
2007, nPOD has recovered tissues from over 100 T1D donors
and distributed specimens to approximately 130 projects led
by investigators worldwide. More recently, nPOD established
a programmatic expansion that further links the transplanta-
tion world to nPOD, nPOD-Transplantation; this effort is
pioneering novel approaches to extend the study of islet
autoimmunity to the transplanted pancreas and to consent
patients for postmortem organ donation directed towards dia-
betes research. Finally, nPOD actively fosters and coordinates
collaborative research among nPOD investigators, with the
formation of working groups and the application of team
science approaches. Exciting findings are emerging from the
collective work of nPOD investigators, which covers multiple
aspects of islet autoimmunity and beta cell biology.
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Introduction
Type 1 diabetes (T1D) is considered a T cell-mediated auto-
immune disease leading to the chronic destruction of pancre-
atic beta cells. The disease is often diagnosed in childhood or
adolescence, but is also common in adult individuals [1].
Despite significant advances in the identification of
autoantigens and susceptibility genes, most of the clinical
trials conducted so far have resulted in no to modest impact
on preservation of insulin secretion after diagnosis [2]. These
outcomes may reflect to a significant extent our incomplete
knowledge of etiological factors and pathogenic mechanisms
[1, 2], which is also a consequence of the rare access to the
pancreas and other disease-related tissues from patients. Fur-
thermore, existing data from human pancreata are largely from
older studies that could not take advantage of the sophisticated
modern technologies available today. Thus, the field has relied
largely on experimental rodent models of the disease, espe-
cially the nonobese diabetic (NOD) mouse [3], to investigate
the disease pathogenesis. This approach has advantages, but
also several limitations, given the rodent models only partially
reproduce the human condition. Moreover, several key ques-
tions cannot be easily investigated in experimental animals,
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such as epitope specificity, key phenotypic and functional
features of autoreactive T and B cells, the possible presence
of viral infections, potential pathways of beta cell regenera-
tion, and importantly, yet uncovered pathogenic mechanisms
that may play a significant role in disease pathogenesis be-
yond T cell-mediated islet cell destruction. Progress in these
areas could lead to the identification of novel therapeutic
targets and guide strategies for modulating multiple disease
pathways, both immune and non-immune, in future clinical
trials. To promote research about the pathogenesis of human
T1D and address the above needs, beginning in 2007, the
Juvenile Diabetes Research Foundation (JDRF) supported the
creation of the JDRF Network for the Pancreatic Organ Do-
nors with Diabetes (JDRF nPOD; www.JDRFnPOD.org).
The JDRF nPOD has three main strategic goals:
1. Recover organs from deceased donors with T1D
(diagnosed or sub-clinical) and establish a repository of
pancreas and other relevant tissues (pancreatic lymph
nodes, spleen, thymus, blood, and others)
2. Distribute donor specimens to approved investigators,
worldwide, to support comprehensive and diversified
studies of human T1D
3. Promote and coordinate collaboration and team science
approaches, by establishing and managing project inter-
actions and focused working groups, to achieve the most
comprehensive understanding of human T1D
This article provides an overview of the JDRF nPOD, both
in terms of its operational models and the discoveries of nPOD
investigators that have been recently contributed to the scien-
tific literature.
The JDRF nPOD Operational Model
The nPOD operational model and standard operating proce-
dures (SOP) have been recently described in detail [4, 5] and
are illustrated in Fig. 1. In the USA, nPOD staff members
work with over 50 organ procurement organizations (OPOs),
tissue banks, and medical examiners, directly or indirectly,
through referral organizations such as the International Insti-
tute for the Advancement of Medicine and National Disease
Research Interchange, to obtain referrals of organ donors.
Organs offered to nPOD are accepted if processing can begin
within 24 h of cold ischemia time (since the organ is cooled
with a cold preservation solution) to ensure the highest quality
of the tissues for cutting-edge research applications. The
nPOD Organ Processing and Pathology Core (OPPC) in
Gainesville, Florida, processes tissues according to SOP
(available at http://www.jdrfnpod.org/for-investigators/
standard-operating-procedures/) [5–7]. Tissues and their
samples are inventoried and baseline characterization
performed including DNA and RNA quality and pancreas
histopathology before distribution to investigators worldwide.
nPOD actively seeks organ donors with T1D, with partic-
ular emphasis on those with shorter disease duration that are
more likely to still have detectable islet autoimmunity and
residual insulin-positive beta cells. Recent onset T1D may
sometimes be diagnosed when a patient has developed dia-
betic ketoacidosis (DKA) and has been admitted to an emer-
gency room; nPOD established a partnership with the Pediat-
ric and Critical Care sections of the American College of
Emergency Physicians (ACEP), to engage pediatric physi-
cians in the referral of thankfully rare but unfortunate deaths
resulting from complications of DKA [8, 9].
To identify donors who might have had asymptomatic
prediabetes, characterized by islet immune infiltrates
(insulitis) in the absence of diabetes symptoms, nPOD has
enabled several OPOs to screen non-diabetic donors for auto-
antibodies associated with T1D risk. nPOD provides the OPO
clinical laboratories with training, protocols, and reagents so
that their staff can rapidly (3 h) screen donors for autoanti-
bodies to the GAD65, IA-2, and ZnT8 autoantigens (a cus-
tomized assay kit developed by Dr. Clive Wasserfall from
standardized ELISAs (KRONUS, Boise, ID)).
The nPOD repository currently includes specimens from
100 donors with T1D, including donors with recent onset
diagnosis, and from 22 non-diabetic donors with islet autoan-
tibodies. At least 19 donors have been identified with insulitis
in their pancreas, including donors of pediatric age. An up-
dated list of donors is maintained on the nPODwebsite (http://
www.jdrfnpod.org/for-investigators/donor-groups/). nPOD
also recovers donors with type 2 diabetes (T2D), as a
comparison to T1D donors and to study pathways of beta
cell physiology and pathology that can also be relevant to
T1D. Finally, nPOD recovers organs from donors affected
with gestational diabetes and cystic fibrosis; non-diabetic
donors are also accepted as controls.
nPOD Investigators and Collaborative Working Groups
Investigators interested in accessing nPOD tissues submit a
description of the scientific project they intend to carry out
using donor specimens. The project is reviewed by either an
academic or industry Tissue Prioritization Committee (TPC),
depending on the investigator’s affiliation. The nPOD TPC
will typically approve projects that have scientific merit and
are feasible, and often will provide critical guidance and
constructive feedback, both in terms of scientific design and
strategic considerations that take into account sample avail-
ability and relevance to the study. Investigators are also
prompted to embrace nPOD policies about data sharing and
collaboration (described below). Indeed, once a project is
approved, investigators are encouraged to take an active role
in nPOD research activities, beyond the conduct of their own
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study. In fact, they are made aware of collaborative opportu-
nities within the network, either with specific investigators or
with working groups. The nPOD staff promotes interactions
among investigators by organizing periodic web-based meet-
ings (webinars) to review data and discuss scientific projects
or provide training on the use of the online pathology system.
In addition, nPOD holds an annual investigators’ meeting
where data, most often unpublished, are presented. Indeed,
nPOD is implementing “real-time” data sharing to best take
advantage of the coordinated analyses of donor specimens by
multiple investigators. Thus, investigators are given the op-
portunity to share results prior to publication, amongmembers
of the nPOD network, and this facilitates changes in the
experimental strategy, reconciliation of discordant findings,
as well as case selection during the course of a project. Data
sharing is made possible by the creation of DataShare, a
collaborative web-based tool for data upload and communi-
cation [4].
Moreover, nPOD has developed collaborative working
groups focused on major research areas where questions are
many and complex and will likely require a team science
approach for significant progress to be made. Thus, interested
investigators begin webinar discussions of a major topic and
collectively define critical questions to address in the context
of a collaborative experimental strategy where synergies can
be exploited. For example, nPOD has established working
groups on viral etiology (nPOD-Virus), autoreactive T cells
(nPOD-T), and extracellular matrix components (nPOD-Ma-
trix), and a group on beta cells (nPOD-Beta Cell) is develop-
ing. Since inception, nPOD has provided tissue specimens in
support of about 130 projects led by investigators around the
world. nPOD-supported projects have a broad scope and
cover critical research areas relevant to T1D, including islet
autoimmunity, environmental factors, beta cell physiology
and dysfunction, as well as pancreas development and remod-
eling, with emphasis on beta cell regeneration, trans-differen-
tiation, and dedifferentiation. nPOD samples are analyzed
with diverse and advanced methodological approaches for
immunohistochemistry, immunofluorescence, electron mi-
croscopy, proteomics genotyping, RNA sequencing, gene
expression, multi-parameter flow cytometry, and more.
The nPOD-Transplantation Initiative
Studies we conducted at the University of Miami in T1D
recipients of simultaneous pancreas-kidney (SPK) transplants
have revealed that approximately 5–6 % of such patients will,
on long-term follow-up, develop recurrence of T1D in the
pancreas allograft [10, 11]. While this concept was demon-
strated in the mid-1980 in identical twins or HLA identical
recipients of segmental pancreas grafts from living-related
donors that were not or were only minimally immunosup-
pressed [12–15], our studies show that disease recurrence may
occur despite immunosuppression that prevents rejection and
largely resembles the features of T1D [11]. Indeed, we have
identified several patients in whom we have shown the
following:
1. On post-transplant follow-up, reappearance of autoanti-
bodies, months to more often years prior to diabetes
recurrence, correlating with increased risk of diabetes
recurrence [11, 16, 17]
Fig. 1 Operational scheme of the
JDRF nPOD. The scheme
illustrates interaction with the
organ procurement organization
to identify organ donors relevant
to nPOD research and the nPOD-
Transplantation model that allows
pancreas transplant recipients to
consent for organ donation to
nPOD to support T1D research.
Tissues are distributed to investi-
gators and working groups to
support advances in research and
hopefully the discovery of novel
therapeutic targets
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2. At presentation of diabetes recurrence, severe, insulin-
requiring hyperglycemia, in the absence of rejection and
stable exocrine pancreas (urine amylase) and kidney (se-
rum creatinine) graft function, yet in the presence of
selective loss of C-peptide secretion
3. In the pancreas transplant biopsy, the presence of insulitis
and/or beta cell loss, at the same time when islet cell
autoantibodies and autoreactive T cells are present in the
circulation and in the pancreas transplant-associated
lymph nodes [11]
4. The presence of autoreactive T cells in the circulation that
correlated with disease activity and progression; in fact, in
patients that received additional immunosuppression in
the attempt to salvage the residual B cell mass demon-
strated at biopsy, autoreactive T cells were no longer
detected after treatment but reappeared on later follow-
up. Their return was followed by further and complete
loss of C-peptide [11]. Moreover, we found that
autoreactive T cells in the circulation were often present
in the pancreas transplant lymph node (unpublished).
5. The demonstration that antigen-specific autoreactive T
cells isolated from these patients could mediate beta cell
destruction when transplanted with human islets in im-
munodeficient mice. Moreover, the T cell receptor se-
quences (V-beta and CDR3) in samples collected over
time suggested a memory phenotype [11, 18] and more
recent phenotypic studies show that these autoreactive T
cells are memory cells, including in the insulitis lesion
(unpublished).
Importantly, the biopsies of the transplanted pancreas in
our cases with diabetes recurrence revealed insulitis and beta
cell loss that did not appear dissimilar in severity and patho-
logical features from nPOD donors with spontaneous disease
in whom insulitis is present in their native pancreas. Figure 2
shows an example of insulitis in the transplanted pancreas
from a patient with recurrence of T1D. Thus, biopsies from
transplanted patients could help us better understand human
disease and could help pinpoint molecular targets expressed
by autoreactive T and B cells. An important consideration is
that patients who develop T1D recurrence appear to carry
memory autoreactive lymphocytes that are reactivated after
transplantation and many years after the onset of the original
disease. It would seem likely that these cells might represent
highly disease relevant populations, and thus, studying their
antigen specificity and functional/phenotypic features could
help us identify important therapeutic targets. Moreover, de-
tailed clinical history and therapeutic regimens are fully doc-
umented and can support full interpretation of research data.
Therefore, we believe that tissues from immunosuppressed,
transplanted patients can potentially be of critical importance
in addressing key questions about T1D and for developing
new means to cure it. Given the relative difficulty of
identifying organ donors with active islet autoimmunity and
insulitis, specimens from these patients represent an important
additional source of research samples for the nPOD
community.
Studies of biopsies from pancreas transplant recipients with
recurrent disease can also be relevant to study beta cell regen-
eration and other mechanisms of pancreas remodeling. Pan-
creas transplant biopsies from several of our patients with
recurrent autoimmunity revealed the presence of ductal cells
expressing insulin [19]. These cells expressed the pancreatic-
duodenal homeobox-1 transcription factor (PDX-1). In one
patient, the one with the most severe B cell loss in islets
(virtually complete), we detected rare insulin+CK-19+PDX-
1+ cells expressing Ki-67, indicating proliferation. In the same
patient, some insulin+CK-19+ ductal cells expressed
chromogranin A, suggesting further endocrine differentiation.
While the patient remained insulin-dependent after the devel-
opment of recurrent diabetes, these findings provide evidence
for a mechanism of tissue remodeling and B cell regeneration
involving ductal cells in the human transplanted pancreas.
Other studies have shown similar changes in human pancreata
with chronic autoimmune pancreatitis [20], chronic pancrea-
titis [21], in streptozotocin-treated nonhuman primates [22]
and in various rodent models [23]. It is possible that chronic
immunosuppression, as given to transplant recipients, could
allow for some level of beta cell replication in the native
pancreas, but addressing this question has proven difficult in
recent clinical studies [24] and may require studies of the
native pancreas if this can be recovered from immunosup-
pressed transplant recipients.
In 2012, based on the above considerations, nPOD initiated
a programmatic expansion, called nPOD-Transplantation, in
which patients with T1D who are recipients of pancreas
transplants consent for directed, postmortem donation to the
nPOD program. This new program is pioneering an approach
that allows T1D recipients of pancreas allografts to consent for
postmortem donation of both their transplanted and native
pancreata to nPOD, so that their organs can support diabetes
research (Fig. 1). We currently have a quite high acceptance
rate, with approximately 85 % of our transplant recipients
consenting to postmortem donation. Recovery would then
be possible through OPOs and tissue banks. We believe that
eventually the opportunity for postmortem donation should be
offered to all patients with T1D who desire to direct organ
donation in support of diabetes research. With growing de-
mand for tissue from investigators, such an approach would
enhance nPOD’s ability to recover more relevant cases with
more clinical detailed medical history. With several large
clinical research studies enrolling thousands of patients and
relatives, interfacing with such initiatives would further the
nPOD mission and ultimately advance diabetes research.
Moreover, the nPOD-Transplantation program is
implementing means to recover both the native and
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transplanted pancreas not just after passing, but through
performing biopsy of living patients as well in relation to
clinical course and relevance to patient care. Accordingly,
nPOD-Transplantation has since inception obtained and made
available to investigators pancreas transplant biopsies from
several patients with diabetes recurrence, and showed that
insulitis was also present. There are currently five transplant
cases deposited in the nPOD repository with collaborative and
coordinated investigations presently ongoing, which cover
several key questions related to disease pathogenesis.
New Findings from nPOD-Supported Studies
During the last few years, many papers have reported novel
findings based on the study of nPOD samples [25–27, 28•, 29,
30, 31••, 32–38, 39•, 40, 41, 42•, 43, 44•, 45, 46•, 47•]. Major
findings emerging from these studies are summarized below:
1. A key question posed when nPOD was established was
whether individuals with autoantibody (single or multi-
ple) would have insulitis in the pancreas [26, 48, 49]. To
date, insulitis has been demonstrated in two of three non-
diabetic donors with multiple autoantibodies but not in
any of the 18 donors with a single autoantibody. Although
such donors likely did not have a relative with T1D and
rarely were found to carry high-risk HLA types for T1D,
these findings are in agreement with the analysis of tissue
blocks from pancreata that were processed for islet isola-
tion in Europe [49] and with the well-established low risk
of T1D demonstrated by prospective follow-up of pa-
tients’ relatives with a single autoantibody [50]. However,
a number of studies are discovering evidence for abnor-
malities affecting the pancreas of donors with
autoantibodies, perhaps pointing at some initial stages in
the disease pathogenesis that may or may not necessarily
progress to overt disease but could be important co-factors
in their own right or if more sustained autoimmunity was
triggered.
2. Examination of nPOD specimens also shows that human
insulitis is rarely as severe as reported in the NODmouse,
an experimental model that presents striking similarity
with the human disease [3], even in newly diagnosed
patients. This is consistent with the cases previously re-
ported in the literature [51] and in biopsies recently ob-
tained at onset from living, newly diagnosed patients from
the DiVid study in Norway [52]. A group of nPOD
investigators has recently come together and conducted
an extensive pathology review of T1D cases from histor-
ical cases and contemporary nPOD cases, and have re-
ported a consensus definition of human insulitis that is
hoped will provide consistency for interpretation and data
comparison across future studies [53••]. Another impor-
tant finding is that insulitis may be present in some cases
for many years after diagnosis [31••], further supporting
the concept that islet autoimmunity is a chronic process
even after diagnosis, which was raised in earlier studies
[54]. This is also consistent with the finding that a signif-
icant proportion of patients express autoantibodies for
many years after diagnosis, as shown for example in
transplant recipients when tested before transplantation
[55]. In our cohort, approximately 40 % of patients
expressed one or more autoantibodies at the time of
transplantation [17].
3. Studies on nPOD cases with insulitis reveal that islet
autoantigen-specific CD8 T cells are present in the
insulitis lesion, using MHC tetramers to identify such
cells in the pancreas of nPOD donors. These findings
place those autoreactive T cells at the crime scene and as
such provide as much causal evidence as is possible
through the study of pathology specimens. Thus, those
autoreactive T cells and antigen specificities can be con-
sidered validated therapeutic targets [31••]. Furthermore,
the study produced initial evidence for an evolution of the
inflammatory lesion. In fact, islets from pancreata with
recent diagnosis were infiltrated by autoreactive CD8 T
cells with single antigen specificity, while pancreata from
patients with longer disease duration and insulitis had
autoreactive CD8 T cells with multiple antigen specific-
ities. Such a dynamic evolution may reflect epitope
spreading of the autoimmune response as disease ad-
vances, possibly sustained by progressive release of novel
antigens that follow beta cell death.
4. Another critical area of study deals with how the immune
system loses tolerance to islet cell autoantigens. The dis-
covery that insulin and other self-molecules are expressed
in the thymus in early life linked this mechanism to
Fig. 2 Example on insulitis in the transplanted pancreas from a patient
who had developed recurrent islet autoimmunity despite immunosuppres-
sion. Pancreatic beta cells are stained for insulin (brown); infiltrating
lymphocytes are stained for CD3 (red)
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tolerance, and genetically determined influences of levels
of autoantigen expression were linked to T1D risk and
enhanced probability of generating autoreactive T cells
[56–59]. In the thymus, expression of self-molecules has
been ascribed to thymic epithelial cells and bone marrow-
derived antigen-presenting cells [56, 60, 61] and largely
depend on the Aire transcription factor, also known as the
autoimmune regulator [62]. Following the studies in thy-
mus, cells capable of expressing self-molecules and me-
diate immune tolerance were described in peripheral lym-
phoid tissues as well [60]. The analysis of pancreatic
lymph nodes showed that self-molecule genes are
expressed at reduced levels in T1D compared to non-
diabetic nPOD donors [25]; such a reduction appears
dependent on the induction of alternative splicing of the
Deaf1 transcription factor, which is also linked to the
transcription of self-molecule genes. Alternative splicing
of Deaf1 may be caused by inflammation, which in turn
impairs expression of the eukaryotic translation initiation
factor 4 gamma 3 (Eif4g3) [43]. These studies illustrate
molecular events that may result in lower expression of
self-molecules (e.g., insulin, an autoantigen in T1D) [63]
and impaired induction of peripheral tolerance at a site
that is believed to be key to the regulation and activation
of islet autoimmune responses, the pancreatic lymph
node. nPOD also supported studies that provided a more
in-depth phenotypic analysis of cells that express self-
molecules in peripheral lymphoid tissues, in particular
extra-thymic Aire-expressing cells [64] that are now
known to represent a bone marrow-derived, distinct phe-
notype with similarities to dendritic cells [46•].
5. nPOD studies show that beta cell loss occurs with distinct
patterns, indicating that the disease pathogenesis is likely
heterogeneous and that more than one pathway may ex-
plain beta cell death [27]. However, beta cell loss is not
absolute and, in several patients insulin-positive beta cells
and glucose transporters [29], are detectable for many
years after diagnosis [31••]. These results, together with
the persistence of insulitis, further support the concept that
the disease process is chronic; importantly, these findings
challenge the traditional view that beta cell loss is virtually
complete at the time of clinical onset, as also suggested by
a meta-analysis of previously published cases [65, 66].
Importantly, evidence for significant dysfunction of pan-
creatic beta cells is emerging from unpublished data from
the new onset patients in the DiVid study [52] and from
our own pancreas transplant recipients with disease recur-
rence, in which impaired beta cell function is shown
despite the presence of insulin-positive cells at biopsy.
These findings concur with recent reports showing that C-
peptide secretion can persist in many patients, albeit at
low levels, for several years after diagnosis [28•, 67•, 68•].
Altogether, these findings suggest the hypothesis that
some patients might perhaps benefit from therapy to alter
disease course or promote beta cell regeneration beyond
just a few months after diagnosis; there is now a trend
towards conducting clinical trials in patients with longer
disease duration which will inform us as to whether there
is indeed a wider window of therapeutic opportunity.
6. Novel molecules have now been associated with disease,
including selected chemokines [38]. Key mediators of
endoplasmic reticulum stress were found in islets from
T1D donors, such as C/EBP homologous protein
(CHOP); the immunoglobulin heavy chain (BIP) was
found expressed in insulin-positive islets with insulitis
[36]. Changes in key constituents of the extracellular
matrix were also noted, such as hyaluronan, a glycosami-
noglycan that was dramatically upregulated with the islet
and outside endocrine cells juxtaposed to microvessels in
nPOD donors with T1D; hyaluronan was also present
around infiltrating cells in cases with insulitis. Moreover,
hyaluronan-binding proteins such as inter-α-inhibitor,
versican, and tumor necrosis factor-stimulated gene-6
showed accumulation in hyaluronan-rich areas in pancre-
atic islets with insulitis. Hyaluronan and IαI amassed in
follicular germinal centers and in T cell areas in lymph
nodes and spleens in T1D compared to controls. These
patterns were only observed in tissues from younger
donors with disease duration of less than 10 years. Fur-
thermore, hyaluronan and inter-α-inhibitor were also de-
tected at increased levels in lymph nodes and spleens
(follicular germinal centers and T cell areas) of T1D
donors compared to controls [47•]. Importantly, these
extracellular matrix components have been linked to lym-
phocyte adhesion and migration and to islet inflammation
[32, 69]. Cathepsins were identified as key mediators in
the degradation and loss of integrity of the peri-islet
basement membrane, which allow autoreactive T cells to
penetrate and infiltrate pancreatic islets [42•]. The cyto-
kine IL-15 and its receptor (IL-15Rα) were found
perturbed in the pancreatic islets and serum of patients;
of note, treatment with tofacitinib to manipulate this path-
way resulted in diabetes reversal in NOD mice, providing
rationale from both nPOD specimens and experimental
models for testing this as a new therapeutic option in
clinical trials [44•]. A recent study reported that C4d is
deposited in T1D pancreata [45], specifically in the blood
vessel endothelium and in the extracellular matrix around
exocrine ducts and blood vessels.
7. The nPOD-Virus group is conducting extensive studies
seeking to address key questions about the role of viruses
in T1D etiology. Ongoing analysis of the nPOD samples is
providing additional evidence for an association of entero-
viruses with T1D [39•]. Importantly, signs of enteroviral
infection are seen also in those nPOD donors with a longer
duration of disease; this finding may be explained by
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persistence of a viral infection or by the occurrence of
multiple infections over time. Considering the other findings
pointing at chronicity, any of these two infection patterns
may contribute to chronicity and help explain the patchy
distribution of insulitis and beta cell loss. Ultimately, more
robust information about which viruses are more prevalent
and a better characterization of the type of infection may
provide support for vaccine development and clinical trials.
8. nPOD investigations are exploring the extent to which
beta cell replication might be possible in the human
pancreas. Beta cell replication appears more sustained in
early life. While replication is possible in adult patients, it
is rare [35]. However, in nPOD donors with T2D, treat-
ment with incretins was associated with the presence of
insulin-glucagon double hormone-positive cells; these
might represent a transitional cell type reflecting regener-
ation or pancreas remodeling [41].
9. The analysis of the pancreas bodyweight revealed that T1D
pancreata have reduced weight compared to those of non-
diabetic donors. Importantly, the pancreas weight was also
reduced in donors with autoantibodies [34]. These findings
suggest the hypothesis that exocrine abnormalities might
exist in the T1D pancreas, resulting in reduced weight, and
that such abnormalities may even precede T1D develop-
ment. If so, the reduction of the pancreas weight may not
simply be a consequence of pancreatic atrophy, related to
insulin deficiency, as until recently believed.
Conclusions
In closing, the JDRF nPOD is actively promoting the study of
T1D focusing research on the analysis of pancreas and other
relevant tissues from patients. Through its interactions with
OPO and transplant programs, nPOD and nPOD-
Transplantation provide investigators with the rare opportuni-
ty to study specimens with ongoing disease and compare
findings at different time points in the natural history of the
disease and after transplantation, when the immunosuppres-
sion cover may provide additional insight into the immune
responses and possibly regeneration. nPOD is pioneering an
expanded team science approach, involving the coordination
of collaborative efforts and real-time data sharing in the joint
study of a cohort of T1D donors. Studies supported by nPOD
are shedding new light into the complexity and heterogeneity
of the human disease and is challenging the concept that beta
cell destruction is completed and autoimmunity almost
exhausted within a few months from diagnosis. nPOD can
also help in validating therapeutic targets and in this function
contribute to defining strategic direction and priority for clin-
ical trials to interdict T1D.
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